Jane Street
XENE icon

Jane Street’s Xenon Pharmaceuticals XENE Stock Holding History

Jane Street’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Sell
19,700
-192,700
-91% -$10.7M ﹤0.01% 6168
2026
Q1 		$12.4M Buy
212,400
+192,600
+973% +$8.87M ﹤0.01% 2279
2025
Q4 		$887K Sell
19,800
-51,400
-72% -$2.16M ﹤0.01% 6373
2025
Q3 		$2.86M Buy
71,200
+50,600
+246% +$1.78M ﹤0.01% 4308
2025
Q2 		$645K Buy
+20,600
New +$672K ﹤0.01% 6472
2024
Q3 		– Sell
-7,800
Closed -$304K – 10514
2024
Q2 		$304K Sell
7,800
-200
-3% -$8K ﹤0.01% 7783
2024
Q1 		$344K Sell
8,000
-2,600
-25% -$120K ﹤0.01% 7334
2023
Q4 		$488K Sell
10,600
-23,100
-69% -$816K ﹤0.01% 6794
2023
Q3 		$1.15M Buy
+33,700
New +$1.26M ﹤0.01% 4971
2023
Q1 		– Sell
-54,000
Closed -$2.13M – 10052
2022
Q4 		$2.13M Buy
54,000
+700
+1% +$25.5K ﹤0.01% 3776
2022
Q3 		$1.92M Buy
+53,300
New +$1.92M ﹤0.01% 4262
2022
Q2 		– Sell
-20,700
Closed -$633K – 11061
2022
Q1 		$633K Buy
+20,700
New +$620K ﹤0.01% 7038

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Jane Street's XENE Position: Q2 2026 in Review

Jane Street sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 3,468 shares — an estimated $193K sold.

Jane Street first reported a position in XENE in Q1 2022 and held it in 13 quarters. The position peaked at $3.61M in Q3 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Jane Street reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 3,468 Xenon Pharmaceuticals shares in Q2 2026, an estimated $193K.
  • Jane Street first reported a position in Xenon Pharmaceuticals in Q1 2022 and held it in 13 quarters.
  • Jane Street's Xenon Pharmaceuticals position peaked at $3.61M in Q3 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.